Shivani Nanda

Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials

David S. Hong, Steven G. DuBois, Shivaani Kummar et al. · The Lancet Oncology · 2020 · 994 citations · Full text

Medicine, Oncology, Immunotherapy +14

Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial

Nick Thatcher, Fred R. Hirsch, Alexander Luft et al. · The Lancet Oncology · 2015 · 475 citations · Full text

Medicine, Oncology, Pharmacology +13

Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study

Arvind Dasari, Sara Lonardi, Rocio García‐Carbonero et al. · The Lancet · 2023 · 323 citations · Full text

Medicine, Oncology, Pharmacology +9

Short- and long-term effects of fraternity and sorority membership on heavy drinking: A social norms perspective.

Kenneth J. Sher, Bruce D. Bartholow, Shivani Nanda · Psychology of Addictive Behaviors · 2001 · 232 citations

Social Sciences, Social Psychology, Sociology +12

Activity of larotrectinib in TRK fusion cancer patients with brain metastases or primary central nervous system tumors.

Alexander Drilon, Steven G. DuBois, Anna F. Farago et al. · Journal of Clinical Oncology · 2019 · 79 citations

Medicine, Oncology, Pharmacology +17